On October 6, 2023, the Drug Enforcement Agency (DEA) and the Department of Health and Human Services (HHS) entered into the second phase of a temporary ruling, effectively enabling the prescription of controlled substances via telemedicine until the closure of 2024. This is a continuation of the temporary prescribing flexibility introduced at the onset of the COVID-19 pandemic in 2020, as reported by JD Supra .
Under normal circumstances, controlled substances, as classified by the DEA, could only be prescribed after in-person medical evaluation. However, the outbreak of the pandemic and its associated restrictions prompted this flexibility to enable ongoing treatments and medication supply despite physical distance or quarantine protocols. This amendment to the law and regulation has marked a significant shift in the way controlled substances are handled within the legal and medical sectors.
The DEA and HHS’s decision to extend these flexibilities through the end of 2024 illustrates the transformative, yet necessary adaptations health care and legal systems may require to maintain essential services available amid future global health crises of similar magnitude.
This extension also paves the way for in-depth discussions surrounding the benefits and potential risks of online healthcare and telemedicine as a viable long-term practice, especially in relation to the handling and prescribing of controlled substances. This conversation will, undoubtedly, necessitate multidisciplinary collaboration, combining insights from legal, healthcare, and technological professionals alike.
As these developments continue to unfold, it is crucial for legal stakeholders within healthcare entities, law firms, and corporations to stay informed and prepared for the ensuing implications and potential legislative changes.